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Abstract
Objective To conduct a systematic review of the literature and
meta-analyses to fill the gaps in knowledge on potassium intake and
health.
Data sources Cochrane Central Register of Controlled Trials, Medline,
Embase, WHO International Clinical Trials Registry Platform, Latin
American and Caribbean Health Science Literature Database, and the
reference lists of previous reviews.
Study selection Randomised controlled trials and cohort studies
reporting the effects of potassium intake on blood pressure, renal
function, blood lipids, catecholamine concentrations, all cause mortality,
cardiovascular disease, stroke, and coronary heart disease were
included.
Data extraction and synthesis Potential studies were independently
screened in duplicate, and their characteristics and outcomes were
extracted.When possible, meta-analysis was done to estimate the effects
(mean difference or risk ratio with 95% confidence interval) of higher
potassium intake by using the inverse variance method and a random
effect model.
Results 22 randomised controlled trials (including 1606 participants)
reporting blood pressure, blood lipids, catecholamine concentrations,
and renal function and 11 cohort studies (127 038 participants) reporting
all cause mortality, cardiovascular disease, stroke, or coronary heart
disease in adults were included in the meta-analyses. Increased
potassium intake reduced systolic blood pressure by 3.49 (95%
confidence interval 1.82 to 5.15) mm Hg and diastolic blood pressure
by 1.96 (0.86 to 3.06) mm Hg in adults, an effect seen in people with
hypertension but not in those without hypertension. Systolic blood
pressure was reduced by 7.16 (1.91 to 12.41) mm Hg when the higher
potassium intake was 90-120 mmol/day, without any dose response.
Increased potassium intake had no significant adverse effect on renal
function, blood lipids, or catecholamine concentrations in adults. An
inverse statistically significant association was seen between potassium
intake and risk of incident stroke (risk ratio 0.76, 0.66 to 0.89).
Associations between potassium intake and incident cardiovascular
disease (risk ratio 0.88, 0.70 to 1.11) or coronary heart disease (0.96,
0.78 to 1.19) were not statistically significant. In children, three controlled
trials and one cohort study suggested that increased potassium intake
reduced systolic blood pressure by a non-significant 0.28 (−0.49 to 1.05)
mm Hg.
Conclusions High quality evidence shows that increased potassium
intake reduces blood pressure in people with hypertension and has no
adverse effect on blood lipid concentrations, catecholamine
concentrations, or renal function in adults. Higher potassium intake was
associated with a 24% lower risk of stroke (moderate quality evidence).
These results suggest that increased potassium intake is potentially
beneficial to most people without impaired renal handling of potassium
for the prevention and control of elevated blood pressure and stroke.
Introduction
Non-communicable diseases are the leading cause of death
globally, killing more people each year than all other causes
combined.1-3Elevated blood pressure and hypertension aremajor
risk factors for cardiovascular diseases, especially coronary
heart disease, stroke, and heart failure, as well as renal failure.4
Although non-communicable diseases disproportionately affect
adults, they and their risk factors are becoming more prevalent
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in paediatric populations. Diet related non-communicable
diseases may take years or decades to manifest, and delaying
the onset of these diseases could improve lives and result in
substantial cost savings.5 6Much of the human and social impact
caused each year by morbidity and mortality related to
non-communicable diseases could be averted through
interventions that are well understood, cost effective, and
feasible.1
Potassium is an essential nutrient that is needed for maintenance
of total body fluid volume, acid and electrolyte balance, and
normal cell function.7 In the pre-agricultural and
post-agricultural diets of our human ancestors, potassium intake
was very high, often exceeding 200 mmol/day.8 In modern
society, these levels have been markedly reduced. Food
processing reduces the potassium content of food, and a diet
high in processed foods and low in fresh fruits and vegetables
is often lacking in potassium.8 Data from around the world
suggest that the average potassium consumption in many
countries is below 70-80 mmol/day,9 the value recommended
by the 2002 JointWorld Health Organization (WHO)/Food and
Agriculture Organization Expert Consultation,10 and even fewer
countries report an average consumption of 90 mmol/day as
recommended by countries such as the United Kingdom, Spain,
Mexico, and Belgium.11-14 No countries report an average
population consumption of 120 mmol/day as recommended by
the United States, Canada, Republic of Korea, and Bulgaria.15-17
Lower potassium consumption has been associatedwith elevated
blood pressure, hypertension,18 and stroke,19 and higher levels
of consumption could be protective against these conditions.10
Public health interventions aimed at increasing potassium intake
from food are, therefore, potential cost effective measures for
reducing the burden of morbidity and mortality from
non-communicable diseases. However, the evidence on the
potential beneficial effect of increased potassium on blood
pressure and cardiovascular disease is not entirely consistent.
Three systematic reviews with meta-analyses, all published 10
or more years ago, suggest that increased potassium intake
lowers blood pressure in adults with and without
hypertension.20-22 Another systematic review without
meta-analysis also concluded that increased potassium decreased
blood pressure in adults.23However, onemeta-analysis of studies
that included only people with hypertension reported no
significant effect of increased potassium intake on blood
pressure.24 A recent meta-analysis of 11 cohort studies reported
an inverse association between potassium intake and risk of
stroke but found no association with cardiovascular disease or
coronary heart disease.19 No systematic reviews have looked at
the effect of increased potassium intake on potential adverse
effects such as changes in blood lipid concentrations,
catecholamine concentrations, and renal function in adults or
children, or of the effect of increased potassium intake on blood
pressure in children. Additionally, none of the previous reviews
or meta-analyses attempted to determine the optimal level of
intake of potassium for maximum health benefits.
To inform the development of its guideline on potassium intake,
theWHO initiated this review to systematically compile results
from studies in apparently healthy adults and children without
acute illnesses or renal impairment that could compromise
handling of potassium and to conduct meta-analyses to answer
the following questions. (1) What is the effect of increased
potassium intake compared with lower intake on blood pressure,
all cause mortality, cardiovascular disease, stroke, and coronary
heart disease in apparently healthy adults? (2)What is the effect
of increased potassium intake on blood pressure in apparently
healthy children? (3) What is the effect of increased potassium
intake on the potential adverse effects of changes in blood lipid
concentrations, catecholamine concentrations, and renal function
in apparently healthy adults and children? (4) What is the level
of potassium intake that results in themaximum benefit on blood
pressure and risk of mortality and cardiovascular diseases? (5)
Is the effect of increased potassium differentially affected by
the hypertension status of the population, sex, average sodium
or potassium intake at baseline, type of intervention, type of
device or method used to measure blood pressure, study design,
or duration of intervention?
Methods
We conducted this review according to the methods
recommended by the Cochrane Collaboration and documented
the process and results in accordance with the preferred reporting
items for systematic reviews and meta-analyses (PRISMA)
statement for reporting systematic reviews.25 26
Outcome data
The primary outcomes of interest in adults were blood pressure,
all cause mortality, and all incident, fatal, and non-fatal
cardiovascular disease, stroke, and coronary heart disease. We
also examined potential adverse effects such as changes in blood
lipid concentrations (total cholesterol, low density lipoprotein
cholesterol, high density lipoprotein cholesterol, triglyceride
concentrations), catecholamine concentrations, and renal
function and any other adverse effects reported by study authors.
The primary outcomes in children were blood pressure and the
potential adverse effects of changes in blood lipids or
catecholamine concentrations and any other adverse effects
reported by study authors.
Inclusion criteria
We planned to include only randomised controlled trials (both
individual and cluster randomised). Knowing that some
outcomes would probably not have at least three studies meeting
the inclusion criteria, we decided a priori that in the event of an
insufficient number of randomised controlled trials for a given
outcome (less than three), we would include quasi-randomised
trials, non-randomised trials, and prospective observational
cohort studies. Randomised and non-randomised controlled
trials must have allocated at least one group of participants to
increased potassium intake (intervention) and one group to lower
potassium intake (control) for at least four weeks. Cohort studies
must have had a prospective design that measured potassium
intake as the exposure and reported at least one of the outcomes
of interest after at least one year of follow-up. Randomised
controlled trials (but not cohort studies) had to use urinary
potassium excretion from 24 hour urine collections to estimate
actual potassium intake. The controlled trials could not have
concomitant interventions (that is, non-drug interventions,
antihypertensive drugs, or other drugs) in the intervention group
unless those interventions were also applied to the control group,
so the only difference between the groups was the level of
potassium intake. We excluded studies targeting acutely ill or
HIV positive people, people admitted to hospital, or people with
impaired urinary potassium excretion due to a medical condition
or drug treatment.
Search strategy
We first searched the literature for high quality systematic
reviews of randomised controlled trials or cohort studies on the
effect of increased potassium intake relative to lower potassium
intake on the outcomes of interest. We examined the reference
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lists of included studies of an identified review if the inclusion
criteria were in agreement with, or were broader than, the
inclusion criteria defined for the specific objectives of our
review. We reviewed each original reference and compared it
against the inclusion criteria for our review and included those
that met our inclusion criteria.
We did a complete search of the literature on potassium intake
and the outcomes of interest published since the data search of
the identified systematic review(s). We searched the Cochrane
Central Register of Controlled Trials (6 September 2011),
Medline (28August 2011), Embase (25August 2011), theWHO
International Clinical Trials Registry Platform (1 September
2011), and the Latin American and Caribbean Health Science
Literature Database (LILACS) (1 September 2011). Our search
had no language restrictions or additional limits. We examined
the reference lists of included studies for additional studies.
Two reviewers independently screened the output of the search
to identify potentially eligible studies. Complete data search
terms can be found in the supplementary material (online
supporting materials (OSM) 1).
Data extraction, risk of bias, and quality
assessment
Two reviewers independently extracted relevant population and
intervention characteristics of each study by using a standard
data extraction form. A third reviewer checked extracted data,
and all disagreements were resolved through consensus. We
requested any relevant missing information from the original
study authors. In the case of duplicate publications and
companion papers of a primary publication, we evaluated all
available data to maximise the yield of information.
For randomised controlled trials, we assessed the risk of bias
associated with the method of sequence generation (possible
selection bias), allocation concealment (possible selection bias),
blinding (possible performance bias), selective reporting
(possible selective reporting bias), loss to follow-up (possible
attrition bias), and completeness of reporting outcome data
(possible attrition bias). In cohort studies, we additionally
evaluated the risk of bias associated with methods of measuring
exposure (possible bias due to confounding or contamination),
collecting outcome data (possible bias due to inadequate duration
of exposure and performance bias), and selecting study
participants (possible bias due to lack of comparability between
groups). We rated the risk of bias as being low, unclear, or high
according to established criteria.25 27
We used funnel plots to assess for the presence of small study
bias.28 29 We generated “risk of bias graph” and “risk of bias
summary” figures for each study type separately in adults and
children. We used GRADEProfiler software (version 3.6) to
assess the quality of the body of evidence according to the
methodology of grading of recommendations assessment,
development, and evaluation (GRADE).30
Statistical analysis
One reviewer entered data into Review Manager software
(Copenhagen, 2011), and a second reviewer checked data entry
for accuracy. In cases of disagreement, a third reviewer also
evaluated the data and all reviewers made a conclusion based
on consensus.
In the randomised controlled trials conducted in adults, we
estimated potassium intake from 24 hour urinary excretion by
using a conversion factor of 1.3.31
We calculated an overall effect estimate for all dichotomous
data as a risk ratio with 95% confidence interval. We extracted
dichotomous data in the form of a risk ratio or a hazard ratio
from each original cohort study by using the statistical models
that controlled for the greatest number of covariates (to reduce
bias) without controlling for blood pressure, because blood
pressure explains some of the effect that potassium has on
non-communicable disease related outcomes.We compared the
risk of each outcome in the group with the highest potassium
intake against that of the group with the lowest potassium intake
(reference group) to generate an overall effect estimate. We did
a subgroup analysis to test the effect of different levels of intake
on outcomes and used different intake levels from the same
study compared with the same reference group but did not pool
the subgroups.
For randomised controlled trials, we generated an overall effect
estimate for all continuous variables by using the difference in
means, with 95% confidence intervals, between the intervention
and the control groups. When a trial had more than one
intervention group but only one control group, we used the
group with the highest potassium intake in the analysis.
When original study authors assessed outcomes at more than
one time point, we included the data from the latest time point
in overall analyses and used data from all relevant time points
in the subgroup analysis based on study duration. We used the
inverse variance method random effects meta-analysis to
combine data and generate the overall effect estimate.32 For all
analyses, we considered results to be statistically significant at
α=0.05.
We assessed heterogeneity by visual inspection of the forest
plots and with the I2 statistic quantifying inconsistency across
studies.33 34 We considered an I2 statistic of 75% or greater to
be an important level of inconsistency. When we found
heterogeneity, we combined data in a meta-analysis, noted the
heterogeneity, and examined characteristics of individual studies
and subgroups and attempted to explain the heterogeneity.
We defined the following subgroups during the protocol
development with input from the WHO Nutrition Guidelines
Expert Advisory Group to test specific objectives: achieved
potassium intake in intervention or comparison group (<90
mmol/day v 90-120 mmol/day v 120-155 mmol/day v >155
mmol/day) (note: original studies reported urinary potassium
excretion; using a conversion factor of 1.3),31 70 mmol/day
urinary potassium equals approximately 90mmol/day potassium
intake, 90 mmol/day urinary potassium equals 120 mmol/day
intake, and 120 mmol/day urinary potassium equals 155
mmol/day intake); achieved difference in potassium intake
between intervention or comparison and control (<30mmol/day
v 30-60 mmol/day v >60 mmol/day); average potassium intake
at baseline (<50mmol/day v 50-80mmol/day v >80mmol/day);
average sodium intake at baseline (< 2 g/day v 2-4 g/day v >4
g/day); hypertensive status of participants at baseline (with
hypertension vwithout hypertension v undetermined or mixed);
and sex (male v female v mixed). Additional subgroups in
randomised controlled trials only were: type of intervention
(diet or feeding v supplementation v advice); type of device
used to measure blood pressure (automatic v manual); method
of measurement of blood pressure (supine office v seated office
v standing office v unspecified); study design (parallel v
crossover); and duration of intervention (<2 months v 2-4
months v >4 months). We also planned to use these subgroups
to examine reasons for heterogeneity.
We did a sensitivity analysis to examine the effect of removing
studies at high risk of bias from the analysis. For randomised
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f1378 doi: 10.1136/bmj.f1378 (Published 5 April 2013) Page 3 of 19
RESEARCH
controlled trials, we considered a study to be at high risk of bias
if it was graded as inadequate in both the randomisation and
concealment of allocation and in either blinding or loss to
follow-up. For cohort studies, we considered a study to be at
high risk of bias if the measurement method for estimating
potassium intake was a single 24 hour dietary recall or if the
study had high risk of confounding for both measurement
method and a second reason.
Results
Search results
We identified 5310 publications reporting on blood pressure,
blood lipids, or catecholamine concentrations in adults or
children or on renal function, all cause mortality, cardiovascular
disease, stroke, or coronary heart disease in adults. Of these,
we found 5250 in the electronic search and 60 in the references
from published systematic reviews or other sources.19-24 After
we eliminated duplicate publications, clearly irrelevant
publications, and studies that did not reach basic inclusion
criteria, we assessed 75 full text publications for eligibility. We
excluded 31 studies on full text review.We could not determine
the eligibility of seven randomised controlled trials from the
published manuscripts; we requested additional information
that we have not yet received.35-41 We could not pool data from
two studies because they lacked the necessary quantitative
information.42 43 Thus 37 studies identified in the original search
contributed to the systematic review and 35 contributed to the
meta-analyses: 22 randomised controlled trials44-65 and 11 cohort
studies66-76 in adults and one randomised controlled trial77 and
one cohort study78 in children. Figure 1⇓ shows the process of
study selection.
Because of the sparseness of data in children, we reassessed the
17 potentially eligible abstracts in children with broader
inclusion criteria including more than three weeks’ duration and
any controlled design. We excluded 11 abstracts and assessed
six full text articles for eligibility. We excluded four: one was
cross sectional, one did not report an outcome of interest, and
two did not report original data. We included two additional
studies: one randomised controlled trial of three weeks’ duration
and one non-randomised controlled trial.79 80 Therefore, we
included four studies in children: two randomised and one
non-randomised controlled trials and one cohort study.
Randomised controlled trials in adults were conducted in
Australia, Chile, China, Germany, India, Italy, Jamaica, Japan,
Kenya, the Netherlands, New Zealand, South Africa, the United
Kingdom, and the United States. Study duration ranged from
four weeks to 12 months. A total of 1606 participants were
included, with individual study sizes ranging from 12 to 353.
The intervention in one study was dietary advice or education,
as well as a tablet supplement. In two studies, the intervention
was dietary advice or education alone. The intervention in the
remaining 20 studies was the provision of potassium
supplements. For study characteristics, see supplementary
material (OSM2).
The 12 cohort studies in adults were conducted in Finland,
Japan, the Netherlands, Scotland, Taiwan, and the United States;
one study included participants from 40 countries. One study
did not report variance estimates andwas, therefore, not included
in the meta-analysis. In the meta-analysis, a total of 127 038
participants were included, with sample sizes ranging from 443
to 38 726 in individual studies. All cohort studies divided the
sample population on the basis of potassium intake at baseline
and measured all cause mortality or incident, fatal, or non-fatal
cardiovascular disease, stroke, or coronary heart disease over
time.
In children, the three controlled trials were conducted in the
United States and the one cohort study in the Netherlands. The
two randomised trials included a total of 250 boys and girls
aged 13-15 years. The non-randomised controlled trial included
76 adolescents aged 11-14 years. The cohort study measured
596 children 5-17 years of age at baseline, and 253 were
re-measured at the seven year follow-up.
Effect estimates
Blood pressure in adults
Twenty one randomised controlled trials contributed 21
comparisons to the meta-analyses of resting blood pressure in
adults. Increased potassium intake reduced systolic blood
pressure by 5.93 (95% confidence interval 1.70 to 10.15) mm
Hg and diastolic blood pressure by 3.78 (1.43 to 6.13) mm Hg.
Heterogeneity was present in both analyses: I2=96% for the
systolic blood pressure analysis and I2=93% for the diastolic
blood pressure analysis.We independently removed each study
from the analyses to explore the effect on the heterogeneity. We
were able to reduce the I2 to 65% in the systolic blood pressure
analysis by removing one study,52 and we reduced I2 to 55% in
the diastolic analysis by removing two studies.51 52 Increased
potassium intake reduced systolic blood pressure by 3.49 (1.82
to 5.15) mm Hg (fig 2⇓) and diastolic blood pressure by 1.96
(0.86 to 3.06) mm Hg (fig 3⇓).
Table 1⇓ contains results from subgroup analyses. Subgrouping
by baseline hypertension status explained most of the remaining
heterogeneity (figures 2⇓ and 3⇓). Increased potassium intake
significantly reduced systolic and diastolic blood pressure in
the 16 studies targeting people with hypertension (systolic blood
pressure 5.32 (3.43 to 7.20) mmHg; diastolic 3.10 (1.66 to 4.53)
mm Hg) but not the three studies targeting people without
hypertension (systolic 0.09 (−0.77 to 0.95) mm Hg; diastolic
(0.56 (−0.42 to 1.55) mm Hg). When we sub-grouped studies
by achieved potassium intake, we found that when the increased
potassium group consumed 90-120 mmol/day, the reduction in
systolic (7.16 (1.91 to 12.41) mmHg) and diastolic (4.01 (−0.42
to 8.44) mm Hg) blood pressure was larger than in any other
intake group, although the groups were not statistically different
from one another and no clear dose response was apparent.
Our other subgroup analyses showed that increased potassium
intake decreased systolic blood pressure regardless of baseline
potassium intake, blood pressure measurement device, blood
pressure measurement method, the population status of use of
drugs to control blood pressure, the intervention type, or the
study design. When we sub-grouped studies according to the
reported population sodium intake, the greatest decrease in
systolic blood pressure (6.91 (2.29 to 11.53) mm Hg) was seen
in the group of studies with the highest sodium consumption
(>4 g sodium/day); however, this decrease was not significantly
greater than the decrease in the group of studies in which the
population consumed 2-4 g sodium/day (1.97 (0.52 to 3.41) mm
Hg). Increased potassium intake decreased systolic blood
pressure in studies of a duration of less than two months (3.36
(1.78 to 4.94) mm Hg,) or 2-4 months (3.83 (0.95 to 6.72) mm
Hg). Only three studies had a duration of more than four
months,44 46 48 two of which were in people without
hypertension,44 46 and increased potassium did not significantly
reduce blood pressure in this group of studies (−0.02 (−0.90 to
0.85) mm Hg). Reductions in diastolic blood pressure in the
subgroup analyses were less pronounced but similar to those of
systolic blood pressure.
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All cause mortality and disease endpoints in
adults
The meta-analysis of nine cohort studies with nine comparisons
detected a protective effect of higher potassium intake on risk
of incident stroke (risk ratio 0.76, 0.66 to 0.89). The risk of
incident stroke was the least when the intake of potassium in
the comparison group was 90-120 mmol/day (risk ratio 0.70,
0.56 to 0.88), although it was not significantly different from
the result when the potassium intake was <90 mmol/day (0.82,
0.71 to 0.93). Potassium intake had a non-significant relation
with incident cardiovascular disease (risk ratio 0.88, 0.70 to
1.10) and coronary heart disease (0.96, 0.78 to 1.19) (fig 4⇓).
Two cohort studies reported all cause mortality; however, the
results could not be combined in a meta-analysis because one
study did not report an estimate of variance.42 That study
reported a relative risk of death of 0.58 for the 80th centile
versus the 20th centile of potassium intake, but statistical
significance was not reported. The second study had
inconclusive results (risk ratio 1.08, 0.91 to 1.29) when
calculating the risk for every increase of one in standard
deviation (45 mmol/day) in intake of potassium.
Potential adverse effects in adults
Meta-analyses of randomised controlled trials reporting changes
in blood lipids showed no significant adverse effect of increased
potassium on total cholesterol (mean difference −0.12 (−0.33
to 0.09) mmol/L), low density lipoprotein cholesterol (−0.10
(−0.38 to 0.18) mmol/L), high density lipoprotein cholesterol
(−0.01 (−0.13 to 0.11) mmol/L), or triglyceride concentrations
(−0.11 (−0.48 to 0.26) mmol/L) (fig 5⇓). No studies measured
urinary catecholamine concentrations. The meta-analyses of
three randomised controlled trials reporting plasma
catecholamine concentrations detected no effect of increased
potassium intake on plasma adrenaline (−3.94 (−9.22 to 1.34)
pg/mL) or plasma noradrenaline (−4.32 (−23.78 to 15.13)
pg/mL). Three studies measured renal function by serum
creatinine, and the meta-analysis showed that increased
potassium intake decreased serum creatinine by a non-significant
4.86 (−3.87 to 13.59) µmol/L. No studies reported minor side
effects or other potential adverse effects from increased
potassium intake.
Blood pressure and potential adverse effects in
children
In the meta-analyses of the three randomised controlled trials
with five comparisons in children, increased potassium intake
decreased systolic blood pressure by a non-significant 0.28
(−0.49 to 1.05) mmHg (fig 6⇓) and diastolic blood pressure by
0.92 (−0.16 to 2.00) mm Hg. In the cohort study, potassium
intake was inversely related to the rate of increase in blood
pressure over a seven year period; the highest third of potassium
intake had a 1.00 (0.35 to 1.65) mm Hg per year lower increase
in blood pressure than the lowest third.78 No studies that met
the inclusion criteria reported the effect of increased potassium
intake on blood lipid concentrations, catecholamine
concentrations or other adverse effects in children.
Quality of body of evidence
The funnel plots of the set of studies in adults do not confirm
small study bias; however, they also do not provide clear
evidence of no small study bias in the set of studies in adults,
so some small study bias may exist (see supplementarymaterials
OSM3). In children, the number of studies was insufficient to
generate meaningful funnel plots. The summary and graph of
the assessment of other risk of bias (OSM4 and OSM5) suggest
that the entire body of evidence in adults was not at high risk
of bias. One randomised controlled trial in adults was at high
risk of bias61; however, only five studies reported the method
of random sequence generation and allocation
concealment.46 57 58 61 64 The body of evidence in children was at
high risk of bias. Of the four studies, one was a cohort study,78
and one was not randomised.80Only one study reported blinding
of personnel and participants,77 and two studies did not blind
personnel and participants.79 80 In all studies in children, whether
the outcome assessors were blinded was unclear.77-80
According to the assessment of quality of evidence by GRADE
methods,30 the evidence for increased potassium reducing blood
pressure in adults was of high or moderate quality (table 2⇓).
The evidence of no effect of increased potassium on blood lipid
concentrations, catecholamine concentrations, or renal function
was of high quality. The quality of evidence was not
downgraded for any reason. The direct evidence for a protective
effect of higher potassium intake on incident stroke was low
because cohort studies began on the GRADE ranking as low
quality and it was not downgraded for any reason. The quality
of the direct evidence for an effect of potassium intake level on
incident cardiovascular disease and coronary heart disease was
very low. In both cases, the quality of evidence began as low
because of the cohort study design and was downgraded owing
to imprecision (that is, the 95% confidence interval of the effect
estimate crossed one). The low and very low quality of this
evidence reflects that the GRADEmethod defines observational
evidence from cohort studies as low quality. Recognising the
limitations of any biomarker, we considered data on change in
systolic blood pressure as indirect evidence regarding the effect
of sodium intake on risk of cardiovascular disease, stroke, and
coronary heart disease. Blood pressure is recognised as a reliable
biomarker for estimating risk of cardiovascular disease,81 82
because of the well established relation between increasing
blood pressure and increasing risk of cardiovascular diseases,
especially coronary heart disease and stroke.4 83We downgraded
the data owing to indirectness (that is, use of a proxy indicator).
According to the GRADE assessment,30 the quality of evidence
in children showing that increased potassium intake reduces
systolic and diastolic blood pressure was low (table 3⇓). We
downgraded the controlled trials because of a high risk of bias
as described previously and imprecision (95% confidence
interval of effect estimate crossed zero). We did not downgrade
the cohort study for any reason but assessed it as low quality
because of the study design, as per GRADE guidance. We used
the data from the systematic review conducted in adults as part
of the evidence base for estimating the effect of increased
potassium on blood pressure and potential adverse effects in
children and downgraded it from high to moderate in quality
because of indirectness (that is, use of a proxy population for
the target population).
We considered the entirety of the evidence and the quality of
the body of evidence in adults and children in generating
conclusions.
Sensitivity analysis
In the meta-analysis of randomised controlled trials in adults,
we removed the one study at high risk of bias.61 Increased
potassium intake still reduced systolic (3.50 (1.82 to 5.15) mm
Hg) and diastolic (2.95 (1.06 to 4.84) mm Hg) blood pressure.
We removed cohort studies from the meta-analyses that
measured exposure to potassium intake through one 24 hour
dietary recall.70 75 Increased potassium was still associated with
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having a protective effect on risk of stroke (risk ratio 0.79, 0.66
to 0.95) and had no association with risk of incident coronary
heart disease (0.89, 0.53 to 1.48). We removed the study that
did not have random treatment allocation from themeta-analyses
in children,80 and we saw little effect on the reduction in blood
pressure (0.27 (−0.62 to 1.15 mm Hg).
Discussion
The results from our meta-analyses of 22 randomised controlled
trials in adults confirm that increased potassium intake reduces
systolic and diastolic blood pressure. Our review is the first to
document through a systematic search of the literature and
meta-analyses that increased potassium has no adverse effect
on blood lipid concentrations, catecholamine concentrations,
or renal function in adults.We found a beneficial effect of higher
potassium intake on risk of incident stroke but not of total
cardiovascular disease or coronary heart disease; however,
because few studies have reported these outcomes, detecting an
effect is difficult even through meta-analysis.
Benefits of increased potassium
Our results on blood pressure are consistent with three previous
meta-analyses, and a fourth systematic review without
meta-analysis, of trials comparing higher potassium with lower
potassium intake.20-23 One previous meta-analysis restricted to
studies conducted in people with hypertension reported no effect
of potassium supplementation on blood pressure.24 The
discrepancy in results could be due to that review having
included only six studies and 483 participants, whereas our
review included 22 studies and 1892 participants, providing
much more power to detect an effect. The meta-analyses of 11
cohort studies in adults suggest an association between higher
potassium intake and reduced risk of stroke. These results are
consistent with the previous meta-analysis of cohort studies,
which reported that a 42 mmol/day higher potassium intake was
associated with a 21% lower risk of stroke.19
Our review was also the first in children and found a
non-significant reduction in blood pressure. Importantly, we
showed through a systematic search of the literature the lack of
data in children. Only three controlled studies with 156 children
met the inclusion criteria for the meta-analysis, so the lack of
significant effect may reflect lack of statistical power. The
suggestion of a beneficial effect in the controlled trials was
supported by the one cohort study in children, which also
reported a beneficial effect of higher potassium intake on blood
pressure. Because renal function, and thus the body’s main
mechanism for controlling potassium balance, is fully developed
early in childhood, potassium intake might be expected to have
the same relation with blood pressure and the other health
outcomes explored in children as in adults. Therefore, findings
in adults can provide some support for an effect of increased
potassium intake on blood pressure in children. Nevertheless,
high quality randomised controlled trials in children are
warranted to explore this relation further.
The meta analysis of 16 randomised controlled trials in adults
with hypertension and in the two randomised controlled trials
conducted in a mixed group of people with and without
hypertension found that increased potassium intake decreased
systolic blood pressure. However, potassium had no detectable
effect on blood pressure in themeta-analysis of three randomised
controlled trials conducted exclusively in people without
hypertension. However, the studies in people without
hypertension were of relatively short duration and did not
consider the effect that increased potassium intake may have
over time on the prevention of elevated blood pressure. Given
the high prevalence of hypertension in adult populations,2 and
the relatively low potassium intake globally,9 84 85 populations
around the world will probably benefit from increased potassium
intake. Elevated blood pressure is the leading risk factor for
mortality globally, accounting for almost 13% of deaths.3 The
decrease in blood pressure caused by increased potassium intake
can have important public health benefits at the population level.
For example a decrease of 2 mm Hg in diastolic blood pressure
in the population of the United States could prevent an estimated
67 000 coronary heart disease events and 34 000 stroke events
every year.86 Researchers estimate that a 5 mm Hg reduction in
systolic blood pressure in the population of the United Kingdom
could reduce the prevalence of hypertension by 50% in that
country.87
Through subgroup analysis, we attempted to assess if the type
of intervention (supplements versus dietary changes) affected
the relation between increased potassium intake and the
outcomes of interest. Increasing potassium intake through dietary
supplements and through dietary changes both reduced systolic
blood pressure, suggesting that the vehicle of increased
potassium intake can be food and does not have to be a
supplement. The results from the cohort studies support this
claim, as all cohort studies considered groups of varying dietary
potassium intake and showed a beneficial effect of higher
potassium intake from food on risk of stroke. Moreover,
potassium is found in a wide variety of foods, so people can
achieve a higher potassium intake through increasing
consumption of foods such as fresh fruits and vegetables and
pulses (legumes).
Potential adverse effects
We systematically searched for, compiled, and meta-analysed
all available data on the potential adverse effect of increased
potassium intake on blood lipid concentrations, catecholamine
concentrations, and renal function and found that increased
potassium, either in supplement or dietary form, had no adverse
effects on these outcomes. Other researchers have shown that
in people without renal impairment caused bymedical conditions
or drug treatment, increasing potassium consumption from food
is safe.17 48 88-90 People with impaired urinary potassium excretion
can be at risk of hyperkalaemia, an unhealthy elevated serum
potassium concentration, from increased potassium
consumption.17 The risk is confined to those patients, most of
whom are under medical supervision,17 and they were not
included in this review. In people without renal impairment, the
body is able to efficiently adapt and excrete excess potassium
in the urine when consumption exceeds needs.7 90 Intervention
trials including potassium consumption as high as 400mmol/day
from food for several weeks and 115 mmol/day for up to a year
reported no adverse effects from increased potassium intake.48 90
Some isolated cases of acute toxicity from extremely high
potassium intake in supplement form have been reported,91 but
no cases of toxicity from potassium intake from food have been
reported. Because of the safety of consumption of increased
potassium from food, our objectives did not include testing a
potential upper limit of intake. We did, however, systematically
search for and record any adverse effects reported by study
authors. No studies reported increased side effects, minor
complaints, or major adverse effects in the increased potassium
groups compared with the control groups.
Optimum potassium intake
This review is the first to attempt to determine an optimum level
of potassium intake for affecting health outcomes. Moderate
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and high quality evidence showed that a higher potassium intake
of 90-120mmol/day reduced blood pressure and was associated
with a lower risk of incident stroke. Intake above 120 mmol/day
did not seem to have any additional benefit. However, the
evidence from the randomised controlled trials and cohort
studies in adults was limited in that it did not identify a precise
optimal level of potassium intake for maximum health benefits.
However, if a person consumes 90mmol/day or more potassium
and theWHO recommended sodium intake of less than 2 g/day,92
his or her intake would have a molar ratio of sodium to
potassium of approximately one to one, a ratio considered
beneficial for health.10 31A subgroup analysis of the randomised
controlled trials to explore whether different levels of sodium
intake influenced the effect of potassium on blood pressure
showed no statistically significant difference in the effect
estimates among subgroups based on sodium intake. However,
the results suggest that potassium may be more effective in
reducing blood pressure at higher levels of sodium consumption,
consistent with previous findings.22 The largest benefit was
detected when sodium intake was more than 4 g/day, which is
the intake of most populations globally,93 so increased potassium
intake should benefit most people in most countries. However,
we also found a statistically significant decrease in blood
pressure with increased potassiumwhen sodium intake was 2-4
g/day. Therefore, increased potassium can continue to be
beneficial in terms of blood pressure even as individuals and
populations decrease their sodium intake. Studies examining
both nutrients simultaneously support this concept, showing an
increased benefit with simultaneous reduction in sodium and
increase in potassium compared with changes in one nutrient
individually.94 95
Limitations of study
Some limitations of this review should be noted. The funnel
plots used to assess small study bias were not clear, and some
small study bias may be present. Baseline hypertension status
accounted for most heterogeneity in the analyses, and the
consistency in results after subgrouping by hypertension status
suggests that any such bias did not greatly affect the results or
conclusions. This review did not cover the recommended period
of exclusive breast feeding (0-6 months) or the period of
complementary feeding with continued breastfeeding (6-24
months). The review did not include studies in patients with
acute disease conditions such as HIV positive status, heart
failure, or renal failure. Therefore, the results should not be
interpreted to include those age groups or acutely ill patients,
especially those with impaired renal function and defective renal
potassium handling. We could not test whether the effect of
increased potassium on health differed by the type of potassium
provided in supplements. In supplementation studies, only one
study used potassium citrate, one used potassium bicarbonate,
and one used a combination of the two. All others used
potassium chloride supplements. Therefore, we could not
compare different supplement types. We could not compare
differences by sex, because 20/22 randomised controlled trials
and 9/12 cohort studies were in mixed populations of men and
women. None the less, the overall beneficial effect of increased
potassium on health supports a beneficial effect in both men
and women. Finally, we did not consider the mechanism by
which increased potassiummay affect blood pressure and related
non-communicable disease.
Conclusion
This systematic review provides the most complete picture to
date of epidemiological and clinical trial evidence in humans
of the effect of potassium intake on blood pressure and related
non-communicable diseases in apparently healthy adults and
children without renal impairment that might compromise
handling of potassium. It combines the data from 22 randomised
controlled trials and 11 cohort studies in adults in meta-analyses
and compiles and compares the data from four controlled trials
and cohort studies in children. High quality evidence (based on
GRADE criteria) from studies in adults shows that increased
potassium intake benefits blood pressure without having an
adverse effect on blood lipid concentrations, catecholamine
concentrations, or renal function. Although data from studies
conducted in children are limited, the available evidence
suggests that increased potassium intake might reduce blood
pressure, and consuming more potassium through foods high
in potassium would probably be beneficial for most children.
Low quality evidence (based on GRADE criteria) from cohort
observational studies in adults shows that increased potassium
intake has an inverse association with risk of incident stroke.
Our results also suggest that the most benefit may occur when
people consume at least 90 mmol of potassium a day.
On the basis of the entirety of this evidence and informed by
the expert guidance of the WHO Nutrition Guidelines Expert
Advisory Group, WHO developed its first guideline on
potassium intake,96which states that adults and children without
compromised renal handling of potassium should increase their
potassium intake from food and that adults should consume
more than 90 mmol potassium/day for beneficial effects on
blood pressure and risk of related cardiovascular diseases.
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Tables
Table 1| Estimates of effect of increased potassium on systolic and diastolic blood pressure in adults by subgroups






−1.96 (−3.06 to −0.86)55185721−3.49 (−5.15 to −1.82)65189221Overall
Blood pressure status at
baseline:
−0.56 (−1.55 to 0.42)3772230.09 (−0.77 to 0.95)07573Without hypertension
−3.10 (−4.53 to −1.66)2482815−5.32 (−7.20 to −3.43)2181816With hypertension
Achieved potassium intake in
intervention group†:
−1.35 (−5.31 to 2.60)451832−3.65 (−6.69 to −0.62)01832<90 mmol/day
−4.01 (−8.44 to 0.42)752124−7.16 (−12.41 to −1.91)71286590-120 mmol/day
−0.83 (−1.82 to 0.17)2110519−1.71 (−3.42 to −0.00)53118710120-155 mmol/day




−1.87 (−4.11 to 0.37)664275−4.89 (−7.59 to −2.20)535016<30 mmol/day
−1.63 (−3.04 to −0.21)53113411−1.97 (−3.85 to −0.09)5111691130-60 mmol/day
−3.57 (−6.32 to −0.82)02224−3.01 (−7.03 to 1.02)262224>60 mmol/day
Average potassium intake at
baseline†:
−2.41 (−7.90 to 3.07)741692−3.89 (−7.03 to −0.74)01692<50 mmol/day
−1.53 (−2.80 to −0.25)45126313−3.39 (−5.51 to −1.28)7013721450-80 mmol/day
−3.38 (−4.74 to −2.02)03515−4.11 (−6.26 to −1.97)03515>80 mmol/day
Sodium intake at baseline:
0.00 (−6.12 to 6.12)NA401−2.00 (−11.70 to 7.70)NA401<2 g/day
−1.96 (−3.16 to −0.76)54143515−1.97 (−3.41 to −0.52)421470152-4 g/day
−2.87 (−6.96 to 1.22)743084−6.91 (−11.53 to −2.29)713825>4 g/day
Duration of intervention:
−1.99 (−3.11 to −0.87)093314−3.36 (−4.94 to −1.78)093314<2 months
−1.86 (−3.75 to 0.02)829656−3.83 (−6.72 to −0.95)85107472-4 months
−0.35 (−1.06 to 0.35)068330.02 (−0.85 to 0.90)07183>4 months
Type of blood pressure device
used:
−2.84 (−3.96 to −1.71)060810−3.45 (−5.13 to −1.77)060810Automatic
−1.54 (−2.96 to −0.11)59117510−3.63 (−5.98 to −1.28)76128411Manual
Type of blood pressure
measurement method used:
−4.34 (−7.57 to −1.10)8569213−4.88 (−7.64 to −2.13)5269213Supine office
−1.30 (−2.64 to 0.04)6911347−1.83 (−3.54 to −0.12)6711697Seated office
−4.78 (−9.38 to −0.18)833518−6.94 (−10.63 to −3.25)383518Standing office
0.83 (−4.45 to 6.11)401172−2.51 (−7.87 to 2.85)01172Unspecified
Use of antihypertensive drugs
at baseline:
−1.37 (−2.50 to −0.23)51131212−3.63 (−5.69 to −1.57)72142113Not taking drugs
−3.80 (−8.25 to 0.66)661955−5.85 (−10.61 to −1.08)341955Taking drugs
Type of intervention:
−3.04 (−5.09 to −0.99)88170919−3.31 (−5.07 to −1.55)63174419Supplement
−2.44 (−5.04 to 0.17)572443−4.19 (−6.46 to −1.92)02443Dietary advice or education
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Table 1 (continued)







−1.59 (−3.35 to 0.18)809917−2.74 (−5.08 to −0.39)7810267Parallel
−4.21 (−7.12 to −1.29)8490315−3.99 (−6.13 to −1.86)3286614Crossover
NA=not available.
*Mean difference (inverse variance, random effects model).
†Potassium intake was measured through 24 hour urinary potassium excretion and estimated from urinary excretion by using conversion factor of 1.3.31
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NoneHigh1892 (21)MD 3.49 lower (5.15 to 1.82
lower)
Resting systolic blood pressure* (follow-up
1-36 months; units mmHg; better indicated
by lower values)
Data from cohort studies begin
with GRADE of low; downgraded
owing to imprecision
Very low29067 (4)RR 0.88 (0.70 to 1.11)Cardiovascular disease† (directly
assessed; RR<1 indicates decreased risk
with increased potassium intake)
Data downgraded owing to
indirectness
Moderate1892 (21)MD 3.49 lower (5.15 to 1.82
lower)
Cardiovascular disease†‡ (assessed by
change in blood pressure (mm Hg); better
indicated by lower values)
Data from cohort studies begin
with GRADE of low
Low97 152 (9)RR 0.79 (0.68 to 0.93)Stroke (directly assessed; RR<1 indicates
decreased risk with increased potassium
intake)
Data downgraded owing to
indirectness
Moderate1892 (21)MD 3.49 lower (5.15 to 1.82
lower)
Stroke‡ (assessed by change in blood
pressure (mm Hg); better indicated by
lower values)
Data from cohort studies begin
with GRADE of low; downgraded
owing to imprecision
Very low31 162 (3)RR 0.97 (0.77 to 1.24)Coronary heart disease (directly assessed;
RR<1 indicates decreased risk with
increased potassium intake)
Data downgraded owing to
indirectness
Moderate1892 (21)MD 3.49 lower (5.15 to 1.82
lower)
Coronary heart disease‡ (assessed by
change in blood pressure (mm Hg); better
indicated by lower values)
Only one study reported this
outcome; downgraded owing to
imprecision
Very low1766 (1)RR 1.08 (0.91 to 1.29)All cause mortality (directly assessed;
RR<1 indicates decreased risk with
increased potassium intake)
–High208 (3)MD 0.12 lower (0.33 lower to
0.09 higher)
Total cholesterol§ (follow-up 1-2 months;
units mmol/L; better indicated by lower
values)
–High152 (3)MD 4.32 lower (23.78 lower to
15.13 higher)
Plasma noradrenaline¶ (follow-up 1-2.5
months; units pg/mL; better indicated by
lower values)
–High147 (3)MD 4.86 lower (13.59 lower to
3.87 higher)
Serum creatinine (follow-up mean 1.5
months; units ng/mL filtrate; better indicated
by lower values)
No studies reported this outcome–––Minor side effects (better indicated by lower
values)
MD=mean difference; RR=risk ratio.
*Additional evidence from meta-analysis of 20 randomised controlled trials with 20 comparisons reporting resting diastolic blood pressure is supportive of benefit
of increased potassium on blood pressure (MD 1.96 mm Hg lower, 3.06 to 0.86 lower) (quality of evidence high); meta-analysis of 4 randomised controlled studies
with 4 comparisons reporting ambulatory systolic blood pressure is supportive of benefit of increased potassium on blood pressure (MD 3.04 mm Hg lower, 5.42
to 0.66 lower) (quality of evidence moderate); meta-analysis of 4 randomised controlled trials with 4 comparisons reporting ambulatory diastolic blood pressure is
consistent with benefit of increased potassium on blood pressure (MD 1.24 mm Hg lower, 3.13 lower to 0.66 higher) (quality of evidence moderate).
†Composite cardiovascular disease as reported by original study authors. This variable included some or all of fatal and non-fatal stroke; coronary heart disease;
myocardial infarction; congestive cardiac failure; or episode of coronary revascularisation, bypass grafting, or angioplasty.
‡Data from systolic blood pressure used as evidence for effect of potassium intake on risk of cardiovascular disease, stroke, and coronary heart because blood
pressure is good proxy indicator for risk of these outcomes.45-47
§Additional evidence on relation between potassium intake and blood lipids comes frommeta-analysis of 2 randomised controlled trials with 2 comparisons reporting
high density lipoprotein cholesterol concentration supportive of no effect of increased potassium in blood lipids (MD 0.01 mmol/L lower, 0.13 lower to 0.11 higher)
(quality of evidence high) and meta-analysis of 2 randomised controlled trials with 2 comparisons reporting triglyceride concentration supportive of no effect of
increased potassium on blood lipids (MD 0.11 mmol/L lower, 0.48 lower to 0.26 higher) (quality of evidence high). Only one randomised controlled trial in literature
reported low density lipoprotein concentration; it was consistent with no effect of increased potassium on blood lipids (MD 0.10 mmol/L lower, 0.38 lower to 0.18
higher).
¶Meta-analysis of 3 randomised controlled trials with 3 comparisons reporting plasma adrenaline concentration is supportive of no effect of increased potassium
on catecholamine concentrations (MD 3.94 pg/mL lower, 9.22 lower to 1.34 higher) (quality of evidence high). No studies reporting urinary catecholamine
concentrations were found.
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1 of 3 studies was not randomised;
downgraded owing to high risk of bias
and imprecision.
Low236 (3)MD 0.28 lower (1.05 lower
to 0.49 higher)
Resting systolic blood pressure* (assessed directly
in children; follow-up 0.75-1 month; units mm Hg;
better indicated by lower values)
Downgraded owing to indirectnessModerate1892 (21)MD 3.49 lower (5.15 to 1.82
lower)
Resting systolic blood pressure† (assessed in
adults; follow-up 1-36 months; units mmHg; better
indicated by lower values)
No studies in children reported on this
outcome
–––Total cholesterol (assessed directly in children)
Downgraded owing to indirectnessModerate208 (3)MD 0.12 lower (0.33 lower
to 0.09 higher)
Total cholesterol† (assessed in adults; follow-up
1-2months; units mmol/L; better indicated by lower
values)
No studies in children reported on this
outcome
–––Plasma noradrenaline (assessed directly in
children)
Downgraded owing to indirectnessModerate152 (3)MD 4.32 lower (23.78 lower
to 15.13 higher)
Plasma noradrenaline† (assessed in adults;
follow-up 1-2.5 months; units pg/mL; better
indicated by lower values)
No studies in children reported on this
outcome
–––Minor side effects (assessed directly in children)
No studies in adults reported on this
outcome
–––Minor side effects (assessed in adults)
MD=mean difference.
*One observational cohort study in children is consistent with beneficial effect of increased potassium on blood pressure over time.
†Data from adults used as proxy for children.
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Figures
Fig 1 Flow of studies through screening, inclusion, and exclusion. RCT=randomised controlled trial
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Fig 2 Effect of increased potassium intake on resting systolic blood pressure in adults: by hypertension status and total
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Fig 3 Effect of increased potassium intake on resting diastolic blood pressure in adults: by hypertension status and total
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Fig 4 Association between higher potassium intake and risk of incident cardiovascular disease, stroke, and coronary heart
disease in adults
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Fig 5 Effect of increased potassium intake on blood lipid concentrations, catecholamine concentrations, and renal function
in adults
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Fig 6 Effect of increased potassium intake on resting systolic blood pressure in children. Sinaiko 1993 reported results for
boys and girls separately, and Wilson 1996 reported results for two groups separately on basis of their change in blood
pressure between waking and sleeping hours during pilot phase of study
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